{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:03:59Z","timestamp":1773216239892,"version":"3.50.1"},"reference-count":89,"publisher":"Informa UK Limited","issue":"36","funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.2217\/fon-2020-0586","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T09:36:43Z","timestamp":1598607403000},"page":"3021-3034","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Avelumab and Axitinib Combination Therapy for the Treatment of Advanced Renal Cell Carcinoma"],"prefix":"10.1080","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1399-5946","authenticated-orcid":false,"given":"Maryam","family":"Soleimani","sequence":"first","affiliation":[{"name":"Department of Medical Oncology,BC Cancer Vancouver Centre, \rVancouver,BC,V5Z 4E6,Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4365-7251","authenticated-orcid":false,"given":"Lucia","family":"Nappi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,BC Cancer Vancouver Centre, \rVancouver,BC,V5Z 4E6,Canada"},{"name":"Department of Urological Sciences, The Vancouver Prostate Centre,University of British Columbia, \rVancouver,BC,V6H 3Z6,Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6329-761X","authenticated-orcid":false,"given":"Christian","family":"Kollmannsberger","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology,BC Cancer Vancouver Centre, \rVancouver,BC,V5Z 4E6,Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"e_1_3_3_3_1","unstructured":"Atkins MB ChoueiriTK. Epidemiology pathology and pathogenesis of renal cell carcinoma. (2020). https:\/\/www.uptodate.com\/contents\/epidemiology-pathology-and-pathogenesis-of-renal-cell-carcinoma?search=renal cell carcinoma&source=search_result&selectedTitle=3~150&usage_type=default&display_rank=3"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.028"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303989"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1490019"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.1293"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.688"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198704093161501"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/15216540252774757"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-009-0015-5"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.08.010"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61613-9"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.4940"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.02.012"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.9764"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03120"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30413-9"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0282"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.117"},{"key":"e_1_3_3_23_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1891\/9781617052736","volume-title":"Cancer Immunotherapy Principles and Practice.","author":"Butterfield L","year":"2017","unstructured":"Basic principles of tumor immunology. In: Cancer Immunotherapy Principles and Practice.ButterfieldL, KaufmanH, MarincolaF (Eds). Demos Medical Publishing, NY, USA, 21\u2013228 (2017)."},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00386"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-019-01611-x"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1790"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02022"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24112071"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.17648"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.04.016"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00978"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12069"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_158892"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0420-0"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.010"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0053-3"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS706"},{"key":"e_1_3_3_41_1","unstructured":"Bristol Myers Squibb and Exelixis announce positive topline results from pivotal Phase 3 CheckMate-9ER Trial evaluating opdivo (nivolumab) in combination with cabometyx (cabozantinib) in previously untreated advanced renal cell carcinoma Bristol Myers Squibb. (2020). news.bms.com\/press-release\/corporatefinancial-news\/bristol-myers-squibb-and-exelixis-announce-positive-topline-re"},{"key":"e_1_3_3_42_1","unstructured":"Bavencio (avelumab) package insert. Merck KGaA Darmstadt Germany (2017)."},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00748-2"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0059"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30239-5"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.06.004"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8448"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.25.4047"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.3044"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0746-2"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30364-3"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.2165\/11591240-000000000-00000"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.081"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0652"},{"key":"e_1_3_3_58_1","unstructured":"Pfizer . Inlyta (axitinib). (2020). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202324lbl.pdf"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0455"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70093-7"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr128"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70465-0"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0974-6"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1543"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30107-4"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.690"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00128"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.687"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30778-2"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0314-1"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5578-4"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.544"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.5001"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.101"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.744"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.12.018"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.e16105"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2017.05.19"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.589"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.733"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.4519"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.730"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS764"},{"issue":"6","key":"e_1_3_3_84_1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.2020.38.6_suppl.689","article-title":"Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the U.K. perspective","volume":"38","author":"De Mello RA","year":"2020","unstructured":"De Mello RA , AyoubE, Castelo-BrancoPet al. Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the U.K. perspective. J. Clin. Oncol.38(6), 689 (2020).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy408"},{"key":"e_1_3_3_86_1","unstructured":"US FDA . FDA approves new dosing regimen for pembrolizumab. (2020). https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-new-dosing-regimen-pembrolizumab"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz056"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0054"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.6256"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.609"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.5367"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2020-0586","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:42:15Z","timestamp":1719124935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2020-0586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":89,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.2217\/fon-2020-0586"],"URL":"https:\/\/doi.org\/10.2217\/fon-2020-0586","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-06-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}